Hjem › Aterosklerose › Arizona › Tucson
Aterosklerose kliniske forsøg i Tucson, AZ
5 studier for Aterosklerose søger deltagere på steder i og omkring Tucson (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
RekruttererFase 2
- Pima Heart, Tucson
- Eclipse Clinical Research, Tucson
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
RekruttererFase 3
- Pima Heart, Tucson
- Eclipse Clinical Research, Tucson
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
RekruttererFase 2/3
- AKDHC Medical, Tucson
- Southern Arizona VA Health Care System, Tucson
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
RekruttererFase 3
- Research Site, Tucson
- Research Site, Tucson
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
RekruttererFase 4
- Southern Arizona VA Health Care System, Tucson, AZ, Tucson
Aterosklerose forsøg i andre byer
- Boston, MA10 studier
- Houston, TX10 studier
- Washington, DC9 studier
- Orlando, FL8 studier
- Arlington, VA8 studier
- Hialeah, FL8 studier
- Durham, NC7 studier
- Dallas, TX7 studier
- Memphis, TN7 studier
- Miami, FL7 studier
- Las Vegas, NV7 studier
- San Diego, CA6 studier
Andre studier i Tucson
- Brystkræft20 studier
- Ikke-småcellet lungecancer17 studier
- Overvægt17 studier
- Overvægt15 studier
- Metastatisk cancer14 studier
- Kræft (alle typer)12 studier
- Kardiovaskulær sygdom12 studier
- Colorektal kræft11 studier
- Prostatakræft11 studier
- Steatotisk leversygdom10 studier
- Hjertesvigt10 studier
- Højt blodtryk10 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.